Enclomiphene vs Eloralintide
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EnclomipheneGLP-1 / Weight Loss Agonists
Eloralintide- Summary
- Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that stimulates endogenous testosterone production by blocking estrogen negative feedback on the hypothalamus and pituitary. Unlike TRT, it restores testosterone while preserving or increasing sperm production and testicular volume.
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Half-Life
- 5-7 days (long half-life; accumulates)
- ~7 days (estimated, long-acting design)
- Admin Route
- Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 12.5-25 mg per day
- Under investigation in Phase 1/2 trials
- Frequency
- Once daily or every other day
- Once weekly
- Key Benefits
- Restores testosterone to normal range without exogenous androgen administration
- Preserves or increases sperm production and fertility
- Maintains testicular volume (unlike TRT which causes testicular atrophy)
- LH and FSH levels rise, indicating intact HPG axis function
- Option for hypogonadal men desiring fertility
- Oral administration (no injection required)
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Side Effects
- Visual disturbances (rare but class-related SERM effect)
- Mood changes or irritability
- Hot flashes
- Elevated estradiol in some users
- +2 more
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Stacks With
- —
- —